ITGA4 and B-cell chronic lymphocytic leukemia: We recently published data demonstrating equally poor outcomes in the setting of CIT and ibrutinib in CLL patients with bimodal expression of CD49d—characterized by concomitant sub-populations of CD49dpos and CD49dneg clones—compared to homogenous CD49neg CLL.